Clinical Trials Logo

Clinical Trial Summary

Our objective is to obtain human induced pluripotent stem cells from urine samples of PXE patients for further proteomic and metabolomic studies and treatment screening.


Clinical Trial Description

Pseudoxanthoma elasticum (PXE) is a genetic multysystem disorder with cutaneous, ophtalmological and cardiovascular involvement.

PXE is associated with mutations of ABCC6 gene coding for the membrane transporter ABCC6 protein. This transporter is normally expressed in hepatocytes and epithelial cells of renal proximal convoluted tubules.

Thus, PXE could be regarded as a metabolic disease of hepatic and renal origin, with clinical and biological involvement/consequences for remote organs.

The substance transported by ABCC6 protein being still unknown, ethiological PXE treatment does not exist yet. However, ABCC6 deficiency is associated with low level of blood PPi (pyrophosphate), which is natural inhibitor of calcium-phosphate deposition.

The aim of the project is to obtain the renal cells derived from PXE patients for their further usage in proteomic and metabolomic studies, as well as for screening of treatment modalities aimed to correct ABCC6 functional deficiency. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03364504
Study type Interventional
Source University Hospital, Angers
Contact
Status Not yet recruiting
Phase N/A
Start date January 2018
Completion date December 2018

See also
  Status Clinical Trial Phase
Completed NCT02537054 - Intravitreal Aflibercept for Therapy of Patients With Pseudoxanthoma Elasticum (PXE) Phase 2
Completed NCT05569252 - A Study of DS-1211b in Individuals With PseudoXanthoma Elasticum Phase 2
Recruiting NCT05662085 - Progression Rate of Pseudoxanthoma Elasticum-associated Choroidal and Retinal Degeneration
Completed NCT03070860 - What's Happen Under the Calcification Process in Pseudoxanthoma Elasticum N/A
Completed NCT01446393 - Functional and Structural Characterization of Arteriopathy in Pseudoxanthoma Elasticum (PXE) N/A
Completed NCT00470977 - Treatment of Exudative and Vasogenic Chorioretinal Diseases Including Variants of AMD and Other CNV Related Maculopathy Phase 1/Phase 2
Recruiting NCT03758534 - Natural History of GACI With or Without ARHR2 or PXE
Recruiting NCT05734196 - The ENERGY Study: Evaluation of Safety and Tolerability of INZ-701 in Infants With ENPP1 Deficiency or ABCC6 Deficiency Phase 1
Not yet recruiting NCT06462547 - ADAPT Study: Long-term Safety Study of INZ-701 in Patients With ENPP1 Deficiency and ABCC6 Deficiency Phase 2
Recruiting NCT01446380 - Phenotypic Expressions in a French Pseudoxanthoma-Elasticum Cohort N/A
Recruiting NCT03813550 - Intestinal Microbiota and Vitamin K Levels in PXE Patients (IMPROVE Study) N/A
Active, not recruiting NCT02108392 - Characterization of Pseudoxanthoma Elasticum
Recruiting NCT01731080 - Arterial Wall Calcium Load in Pseudoxanthoma Elasticum N/A
Completed NCT00555113 - Evolution of Visual Impairment During Pseudoxanthoma Elasticum N/A
Completed NCT00341419 - Genetic Analysis of Patients With Pseudoxanthoma Elasticum
Withdrawn NCT04441671 - Oral Pyrophosphate Absorption in PXE Disease Phase 2
Recruiting NCT04868578 - PPI Supplementation to Fight ECtopIc Calcification in PXE N/A
Completed NCT05025722 - Pseudoxanthoma Elasticum (PXE) Natural History Biomarkers in PXE Individuals and Their Biological Non-PXE Siblings
Completed NCT01525875 - Magnesium Supplements In The Treatment Of Pseudoxanthoma Elasticum (PXE) Phase 2
Completed NCT05246189 - Employment of Patients With Pseudoxanthoma Elasticum